Acetyl-L-Carnitine in Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

229

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

May 31, 2012

Study Completion Date

December 31, 2012

Conditions
Diabetes Type 2Hypertension
Interventions
DRUG

acetyl-L-carnitine/statin (simvastatin)

"acetyl-L-carnitine: 4 tablets of 500 mg a day~simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability"

DRUG

placebo

placebo: 4 tablets of 500 mg a day simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability

Trial Locations (5)

24020

"Clinical Research Center for Rare Diseases Aldo and Cele Daccò", Ranica

24036

"Hospital Azienda Ospedaliera di Treviglio e Caravaggio Ambulatory of Diabetology", Ponte San Pietro

24100

"Hospital Azienda Ospedaliera Ospedali Riunitidi Bergamo Unit of Diabetology", Bergamo

Unknown

"Hospital Azienda Ospedaliera di Treviglio-CaravaggioUnit of Diabetology and Metabolic Diseases", Romano di Lombardia

"Hospital Azienda Ospedaliera di Treviglio-Caravaggio Unit of Diabetology and Metabolic Disease", Treviglio

Sponsors
All Listed Sponsors
collaborator

Leadiant Biosciences, Inc.

INDUSTRY

lead

Mario Negri Institute for Pharmacological Research

OTHER

NCT00984750 - Acetyl-L-Carnitine in Type 2 Diabetes | Biotech Hunter | Biotech Hunter